This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. Missense mutations in the four and a half LIM domain 1 (FHL1) gene were found to cause X-linked inherited myopathies of both skeletal and heart muscle. However, the mechanisms by which FHL1 mutations impact on FHL1 function and lead to alteration of muscle structure and function have not been deciphered yet. We generated here by Morpholino-modified antisense oligonucleotide-mediated gene knockdown Fhl1-deficient zebrafish embryos. Similar to the human situation, fhl1a-morphants zebrafish displayed severe skeletal and heart muscle myopathy. Whereas ectopic expression of wild-type FHL1 (FHL1 wt) suppressed both skeletal and heart muscle myopathy in fhl1a-morphants zebrafish, overexpression of the FHL1-opathy associated human mutations FHL1-H123Y, FHL1-C132F or FHL1-C224W did not rescue skeletal and heart muscle myopathy in fhl1a-morphants. Overexpression of either FHL1-H123Y, FHL1-C132F or FHL1-C224W in wild-type zebrafish did not induce myopathy in a dominant-negative mode. Altogether these results indicate that FHL1 mutations found to cause X-linked FHL1-opathies in humans consistently lead to severely impaired FHL1 function.
Introduction
The four and a half LIM domains 1 protein (FHL1) is strongly expressed in skeletal and cardiac muscle and localizes to the cytoskeleton, sarcomere, mitochondria and the nucleus [1] [2] [3] . FHL1 is known to play an essential role in skeletal muscle growth and differentiation, acts as a scaffolding protein in sarcomere assembly and is a regulator of skeletal muscle mass and energy metabolism [1, 4, 5] .
Up to date, more than 30 different FHL1 mutations have been identified to cause distinct skeletal and heart muscle disorders, that are referred to as FHL1-opathies [1, 2, 4, [6] [7] [8] [9] [10] [11] . FHL1-opathies usually share several overlapping clinical features such as muscle weakness, progression to contractures, and severe cardiomyopathy, often leading to premature death. The precise pathogenic mechanism by which mutant FHL1 protein causes FHL1-opathy has not been deciphered yet. So far, clinical observations suggest a combination of both loss and gain of FHL1-function effects, both contributing to the clinical presentation of FHL1-opathies: FHL1 protein aggregates suggest a gain of FHL1 function mechanisms, whereas lower FHL1 protein levels indicate a loss-offunction effect in FHL1-opathy patients [5] . To examine for the first time the pathogenetic mechanism by which human FHL1 mutations induce skeletal and heart muscle myopathy in vivo [12] , we performed here loss-of-function and gain-offunction experiments in a zebrafish model of FHL1-opathy and find that mainly lossof-function effects are mediating the impact of the distinct FHL1-opathy associated human mutations FHL1-H123Y, FHL1-C132F and FHL1-C224W on heart and skeletal muscle structure and function.
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Material and Methods

Zebrafish Strains
Care and breeding of zebrafish, Danio rerio, were as described [13] . The present study was performed after securing appropriate institutional approvals (Tierforschungszentrum (TFZ) Ulm University, No. 0183), which conform to the EU Directive 2010/63/EU. It conforms to the Guide for the Care and Use of Laboratory Animals published by the "US National Institute of Health" (NIH Publication No. 85-23, revised 1996) . For all mRNA and morpholino injection procedures the Tü wildtype strain was used.
Histology, transmission electron microscopy, immunostaining and immunoblotting
Histological analysis and electron micrographs of fish embryos were performed as described [14] . For whole-mount, sectioned HE-and immunostainings, embryos were fixed in 4% paraformaldehyde. Immunostaining was performed on paraffin-sections, using a polyclonal anti-FHL1 (Abcam, UK) antibody and a monoclonal anti-Nexilin IgG1 (BD Biosciences, Germany). Secondary antibodies included goat anti-mouse IgG2b-TRITC and goat anti-mouse IgG1-FITC antibodies (Southern Biotech, USA), anti-rabbit IgG-TRITC (Sigma, Germany) antibody, and anti-rabbit IgG-FITC (Molecular Probes, USA) antibody. Western-blots were probed with a monoclonal anti-Myc (Sigma-Aldrich, Germany) as primary antibody.
RNA in situ hybridization and quantitative real-time PCR
Whole-mount RNA in situ hybridization was carried out essentially as described [15] using a digoxigenin-labeled full-length fhl1a and fhl1b antisense probe.
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Morpholino-and mRNA-injection procedures
Morpholino-modified antisense oligonucleotides were directed against the splice donor site of exon 2 (MO-fhl1a: 5'-ATTGTCGTTTAACTCGTACCTTTGC-3') of fhl1a.
A 5-basepair mismatch Morpholino modified antisense oligonucleotide (MO-control) was injected at the same concentrations as control (Genetools, LLC, USA).
Sense-capped RNA was synthesized using the mMESSAGE mMASCHINE system (Ambion) for FHL1 (isoform A, full-length) constructs FHL1-H123Y, FHL1-C132F and FHL1-C224W. RNA was diluted (15, 30, 50 , or 80 ng/μL in 0.2 mol/L KCl and microinjected into one-cell-stage embryos. Siblings from the same pool were injected using 0.2% KCL as control.
Functional assessment
Pictures and video films were recorded and digitized with a Zeiss microscope/MCU II.
The functional assessment of cardiac contractility was carried out as described before [16] . Fractional shortening (FS), atrial and ventricular diameters were assayed with help of the zebraFS software (http://www.benegfx.de).
Statistical analysis
Statistical analysis was performed in Graph Pad Prism. Comparisons between experimental groups were performed using t test for parametric samples. Differences are considered significant at a p < 0.05 significance level and marked with "*", very significant with p < 0.01 are labeled "**" and extremely significant with p < 0.001 are labeled "***".
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Results fhl1a-morphants zebrafish embryos display severe heart and skeletal muscle myopathy FHL1 mutations consistently lead to X-linked inherited heart and skeletal muscle myopathy in humans. However, the mechanisms by which these mutations impact on FHL1 function have not been deciphered yet. Reverse genetic approaches in the vertebrate model organism zebrafish such as Morpholino-mediated knockdown are established methods to decipher genetic mechanisms of both heart and skeletal muscle myopathies in vivo [17] [18] [19] [20] First, to establish a loss-of-function model for FHL1 in zebrafish, we searched for the zebrafish orthologous sequence of human FHL1. As shown in Figure 1A , in the zebrafish, two potential orthologs of human FHL1 exist: fhl1a and fhl1b. In zebrafish fhl1a and fhl1b reside on autosomal chromosome 14 and 10, respectively. Importantly, in zebrafish sex determination and differentiation is not mediated through a dedicated sex-linked chromosome as in humans but rather by polygenic sex determination. As a consequence X-linked transmission of FHL1-opathies, as observed in humans, does not exist in the zebrafish.
Amino acid sequences of zebrafish Fhl1a and Fhl1b are highly conserved from zebrafish to humans, showing a 67% for Fhl1a and 60% for Fhl1b overall amino acid identity with human FHL1, and a 100% conservation within the essential Zinc-binding LIM domains, that are crucial for the integrity and structure of FHL1 ( Figure 1A ). Both zebrafish FHL1 orthologs, Fhl1a und Fhl1b, share 67 % amino acid identity, again with 100 % identity of the Zinc-binding LIM domains ( Figure 1A , light blue boxes).
Next, to evaluate if both zebrafish Fhl1 orthologs of mediate redundant function in zebrafish, similar to duplicate genes in zebrafish [21, 22] , we assayed RNA distribution by whole-mount in-situ hybridization and by immunohistochemistry of Page 6 of 33 both, fhl1a and fhl1b, and found that both are highly abundant in the heart and throughout development (24-120 hpf), next to other organs such as the liver [23] ( Figure 1B-D) . In the skeletal muscle fhl1a localizes to the entire musculature, whereas fhl1b localizes to the pectoral fin musculature [24] (Figure 1B, 1C) . In the heart ( Figure 1D ), fhl1b is predominantly expressed in the cardiac outflow tract, whereas fhl1a is mainly expressed in the myocardium of both heart chambers.
Hence, for further investigations, we concentrated on fhl1a due to its unique cardiac and skeletal muscle expression in the myocardium. To investigate whether structural defects of the skeletal muscle account for the observed skeletal muscle dysfunction, we performed birefringence assays, histological staining and transmission electron microscopy on MO-fhl1a-injected zebrafish embryos. In the birefringence assay of wild-type zebrafish embryos at 72 hpf the well-organized skeletal muscle appeared bright, indicating regular skeletal muscle integrity, as described before [25] . By contrast, skeletal muscle of fhl1a-morphants displayed a general reduction of birefringence as indicator for myopathy and consistent with myofibrillar disorganization in the skeletal muscles ( Figure 2B ) [25] . Typical dark patches of larger skeletal muscle areas are not present, but irregularity of the birefringence indicates degeneration of myofibers. On a histological level ( Figure 2C ), we found myofibrillar disarray and a reduced content of contractile fibers in the skeletal muscle of fhl1a-morphants compared to wild-type zebrafish embryos. Ultrastructural analysis by transmission electron microscopy further confirmed the myofibrillar disorganization in the skeletal muscle of fhl1a-morphants.
The content of contractile fibers was reduced to 25,9 % ± 4,3 % in fhl1a-morphants Page 8 of 33 compared to 62,3 % ± 5,4 % in control zebrafish embryos at 72 hpf (area of contractile fibers of striated muscle, n = 3 TEM, p = 0.0127). In addition, intermyofibrillar degeneration was observed including enlargement of the sarcoplasmatic reticulum (SR) in fhl1a-morphants as well as sub-sarcolemmal and inter-myofibrillar accumulation of dysmorphic mitochondria ( Figure 2D ). Reducing bodies were not detectable in the ultrastructural analysis.
In addition to skeletal muscle myopathy, cardiomyopathy was observed in fhl1a-morphants, again recapitulating FHL1-opathy in humans. Cardiac contractility measured by fractional shortening was reduced to 38 ± 3.0 % in fhl1a-morphants (n = 10 embryos in total, three independent experiments, p = 0.0157), compared to 48 ± 1.4 % in control-injected embryos (n = 10 embryos in total, three independent experiments, Figure 3B ). Reduced cardiac contractile function in fhl1a-morphants was accompanied by a significantly reduced heart rate of 88 ± 4.8 bpm (n = 35 embryos in total, three independent experiments) compared to 140 ± 2.7 bpm in controls (n = 35 embryos in total, three independent experiments, p < 0.0001, Figure   3A ). Furthermore, we found in 16 % (n = 24 out of 150 embryos in total, three independent experiments) of fhl1a-morphants different arrhythmias, such as atrial fibrillation, pauses and atrioventricular blocks (exemplary movie in Supplement).
Human FHL1 can suppress FHL1-opathy in zebrafish fhl1a-morphants
To further confirm specifity of loss of Fhl1 function in the zebrafish model by targeted wild-type FHL1 ( Figure 4D ). Heart rate also remained decreased to 74 ± 8 bpm (n= 20 embryos in total, three independent experiments, p= 0.5918) in MO-fhl1a + FHL1-H123Y, 84 ± 14 bpm (n= 20 embryos in total, three independent experiments, 0.3142) in MO-fhl1a + FHL1-C132F and 70 ± 13 bpm (n= 20 embryos in total, three independent experiments, p= 0.6933) in MO-fhl1a + FHL1-C224W, compared to 89 ± 8 bpm (n= 20 embryos in total, three independent experiments) in fhl1a-morphants and 151 ± 1 bpm (n= 20 embryos in total, three independent experiments) in wildtype control embryos. In contrast, the heart rate of fhl1a-morphants could be normalized to 130 ± 3 bpm (n= 20 embryos in total, three independent experiments; p <0.0001) by overexpressing human wild-type FHL1 ( Figure 4E ).
In summary, only wild-type FHL1 was capable of reducing the FHL1-opathic phenotype in fhl1a-depleted zebrafish embryos, whereas missense mutated FHL1-H123Y, FHL1-C132F and FHL1-C224W proteins could not rescue Fhl1a function in fhl1a-depleted zebrafish, indicating that the human missense mutations FHL1-H123Y, FHL1-C132F and FHL1-C224W consistently lead to loss of FHL1-function.
Human FHL1-opathy associated mutations do not act dominant-negatively in vivo
Next, to evaluate, if the FHL1-opathy associated human mutations have in addition to their loss-of-function effect a dominant-negative effect on heart and skeletal muscle in vivo, thereby inducing skeletal muscle and heart muscle myopathy, we ectopically expressed human FHL1-H123Y, FHL1-C132F and FHL1-C224W in wild-type zebrafish embryos. Overexpression of human wild-type FHL1 did not lead to a FHL1-opathic phenotype in wild-type zebrafish embryos since skeletal muscle and cardiac function was normal and did not differ from control-injected zebrafish embryos at 72 hpf ( Figure 5A ). Furthermore, heart rate of zebrafish embryos overexpressing either mutant or wild-type human FHL1 did not significantly differ from control zebrafish embryos (FHL1 wt 139 ± 2 bpm (n= 20 embryos in total, three independent experiments), in FHL1-H123Y 142 ± 2 bpm (n= 20 embryos in total, three independent experiments), in FHL1-C132F 142 ± 3 bpm (n= 20 embryos in total, three independent experiments) and in FHL1-C224W 134 ± 2 bpm (n= 20 embryos in total, three independent experiments), compared to 151 ± 1 bpm in wild-type control embryos at 72 hpf (p = 1.00, p = 0.553, p = 0.6019, p = 0.2579, Figure 5B 
Discussion
Mutations of FHL1 are known to cause a variety of X-linked heart and skeletal muscle disorders in humans. The pathogenic mechanism by which missense mutated FHL1 protein causes FHL1-opathy is not understood yet. So far, a loss-of-function mechanism as well as a gain-of-function mechanism was postulated to contribute to the pathogenesis of FHL1-opathies in humans [5] .
We demonstrated here, that loss of FHL1-function caused cardiomyopathy and impaired skeletal muscle function in zebrafish. By expression of common human FHL1 mutations in the zebrafish, we confirmed a loss-of-function mechanism for the pathogenesis of FHL1-opathies.
Due to its transparency, accessibility to genetic modification and particularly because of its evolutionary conserved genome and molecular mechanisms that control muscle development and function, the zebrafish is a suitable vertebrate model system to study human striated muscle diseases such as cardiomyopathies and muscular dystrophies [17] . We demonstrated here, that targeted knockdown of fhl1a in zebrafish lead to FHL1-opathy in zebrafish embryos with skeletal muscle myopathy accompanied by reduction of contractile fibers, enlargement of the sarcoplasmatic reticulum and accumulation of dysmorphic mitochrondria. Similarly, in other models e.g. in a FHL1-null mouse model, myofibrillar disarray and intermyofibrillar disorganization with accumulation of dysmorphic sarcoplasmatic reticulum and mitochrondria were observed [5] . [1, 29, 31] and are a hallmark of myofibrillar myopathies (MFM) [32] . In our zebrafish model, the examined common mutations of FHL1 found in humans suffering from FHL1-opathies (H123Y, C132Y and C224W) did not impair skeletal muscle and cardiac function when they were overexpressed in vivo. Skeletal muscle did not show any abnormalities in the zebrafish embryos overexpressing human FHL1 mutations H123Y, C132Y and C224W and cardiomyopathy was absent, suggesting that a gain-of-function mechanism of the examined FHL1 mutations did not account for FHL1-opathy in the zebrafish. But, the rabbit polyclonal anti-FHL1
antibody we used to detect the overexpression of human FHL1 in Western blot analysis also sufficiently detects zebrafish Fhl1a and Fhl1b, rendering further investigations on possible interaction of endogenous zebrafish Fhl1 orthologes and human FHL1 impossible. Furthermore, inclusion bodies were not detected in our zebrafish model, indicating that these intracellular FHL1 protein aggregates might not be compulsory for the pathogenesis of FHL1-opathies in zebrafish. This is supported by the fact, that reducing body protein aggregates are also not detectable in all subtypes of FHL1-opathies (e.g. in XMPMA and EDMD) in humans. Furthermore, in FHL1-null mice reducing bodies were not detectable, despite their characteristic FHL1-opathy with severe skeletal muscle myopathy and functional impairment [5] .
However, the formation and accumulation of inclusion bodies is likely to be a chronic process and their absence might be caused by the short life span of 5 days post fertilization of the zebrafish embryos.
The second hypothesis for the pathogenesis of FHL1-opathies is a loss of FHL1-function mechanism. In this case, nonsense-mediated RNA decay or degradation of mutated, misfolded protein might lead to lower FHL1 protein levels thereby impairing FHL1 protein-protein-interactions. This hypothesis is supported by lower expression levels of mutant FHL1 in human muscle biopsies of RBM, XMPMA, SPM or EDMD patients [1, 29, 31] . Importantly, our targeted knockdown of fhl1a in the zebrafish supports the hypothesis of a loss-of-function mechanism in FHL1-opathies. By targeted knockdown of fhl1a we were able to copy FHL1-opathy in the zebrafish including skeletal muscle myopathy, cardiomyopathy and arrhythmias. Furthermore, the fact that, FHL1 function in fhl1a-morphants could exclusively be restored by expression of human wild-type FHL1, but not by expression of missense mutated FHL1, indicates that the examined human mutations (H123Y, C132Y and C224W) lead to a loss of FHL1-function and that a loss-of-function mechanism accounts for FHL1-opathies in humans.
However, in the zebrafish two fhl1 orthologs exist, fhl1a and fhl1b. fhl1a is expressed in the heart and skeletal muscle and its targeted knockdown leads to a characteristic FHL1-opathic phenotype. In contrast to this, fhl1b is located in the outflow tract of the heart and the pectoral fin musculature. Despite this distinct localization patterns in skeletal muscle and heart, the two orthologs, fhl1a and fhl1b, might still mediate redundant functions similar to other duplicate genes in zebrafish [21, 22] . By genetic compensation, a mechanism protecting the zebrafish against the deleterious loss of gene function [33] , the disease phenotype might be mitigated in our zebrafish fhl1a knockdown model. Possibly, this could also be one reason for the absence of specific features of FHL1-opathies in our zebrafish model, e.g. reducing bodies.
Nevertheless, genetic compensation is predominantly present in genetic knockout models such as CRISPS/Cas9 induced knockout zebrafish lines, but is less prominent in Morpholino-modified antisense oligonucleotide-mediated knockdown models [33] .
In conclusion, the characteristic FHL1-opathic phenotype of fhl1a-depleted zebrafish morphants by targeted knockdown implies a loss-of-function mechanism in FHL1-opathies. Moreover, the inability of the three human FHL1 mutations FHL1-H123Y, FHL1-C132F and FHL1-C224W to rescue the FHL1-opathic phenotype in fhl1a-morphants zebrafish confirmed a loss-of-function mechanism of the distinct human missense FHL1 mutations. Hence, the zebrafish is an excellent model to study the pathogenetic mechanisms of mutations and their causality. 
